Arsenic in cancer therapy

Anti-Cancer Drugs

Volumn 16, Issue 2, 2005, Pages 119-127

  Hu, Jiong ^a   Fang, Jing ^a   Dong, Yin ^a   Chen, Sai Juan ^a   Chen, Zhu ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic; Cancer; Leukemia

Indexed keywords

ALPHA INTERFERON; ARSENIC; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUTHIONINE SULFOXIMINE; CASPASE; DITHIOTHREITOL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; I KAPPA B; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MERCURIC CHLORIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HAIR LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; ECG ABNORMALITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOMODULATION; KIDNEY CARCINOMA; LEUKEMIA CELL; LEUKEMIA REMISSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOMA; MITOCHONDRION; MOUSE; MULTIPLE MYELOMA; NAIL; NONHUMAN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; SCID MOUSE; SEZARY CELL; SKIN MANIFESTATION; SYSTEMATIC REVIEW; T CELL LEUKEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA;

EID: 13844281112     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200502000-00002     Document Type: Review

References (65)

1. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. J Am Med Ass 1931; 97:3-5.
2. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6(suppl 2):3-10.
3. Kandel EV, LeRoy GV. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia. Arch Intern Med 1937; 60:846-866.
4. Chan PC, Huff J. Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidemiological evidence. J Environ Sci Health C 1997; C15:83-122.
5. Sun HD, Ma L, Hu XC. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integral Chin West Med 1992; 12:170-172.
6. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
7. Niu C, Van H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315-3324.
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348.
9. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARRα/PML proteins. Blood 1996; 88:1052-1061.
10. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572.
11. Chen Z, Wang ZY, Chen SJ. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 1997; 76:141-149.
12. Awisati G, Tallman MS. All-trans retinoic acid in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16:419-432.
13. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 1999; 18:5278-5292.
14. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15:735-741.
15. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99:3136-3143.
16. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345-3353.
17. Look AT. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst 1998; 90:86-88.
18. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90:124-133.
19. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14:262-270.
20. Zheng YH, Shi Y, Tian CH, Jiang CS, Jin HJ, Chen JJ, et al. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 2004; 23:1239-1247.
21. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94:2102-2111.
22. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93:268-277.
23. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97:264-269.
24. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189:1043-1052.
25. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328-5335.
26. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91:772-778.
27. Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000; 60:3409-3413.
28. L. Blood 2000; 95:1014-1022.
29. 3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001; 15:772-778.
30. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30:729-737.
31. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103:208-215.
32. Nimmanapalli R, BaIi P, O'Bryan E, Fuino L, Guo F, Wu J, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003; 63:7950-7958.
33. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999; 59:1041-1048.
34. Munshi NC. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001; 6(suppl 2):17-21.
35. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60:3065-3071.
36. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1:851-860.
37. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81:796-799.
38. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999; 49:91-102.
39. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003; 2:1155-1164.
40. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98:805-813.
41. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8:3658-3668.
42. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002; 8:566-572.
43. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell Jr RP, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96:1525-1530.
44. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59:6033-6037.
45. 3) on myeloma cells. Leuk Res 2001; 25:227-235.
46. Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72:166-171.
47. Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003; 10:370-374.
48. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16:1835-1837.
49. Hussein MA, Mason J, Saleh NM, et al. Arsenic trioxide (Trisenox) in patients with relapsed or refractory multiple myeloma (MM): final report of a phase II clinical study. Proc Ann Meet Am Soc Hematol 2002; 5138 (abstr).
50. Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol 2003; 110:1-10.
51. Hu XM, Hirano T, Oka K. Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2003; 51:119-126.
52. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, et al. Phase II trial of arsenic trioxide and alpha Interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5:130-134.
53. Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 2003; 121:881-893.
54. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93:278-283.
55. Nasr R, Rosenwald A, El-Sabban ME, Amulf B, Zalloua P, Lepelletier Y, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003; 101:4576-4582.
56. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al. Inhibition of NFkappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102:1028-1034.
57. Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 2003; 27:174-179.
58. Hyun PW, Hee CY, Won JC, Oh PJ, Kim K, Hyuck IY, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300:230-235.
59. Lin X, Tascilar M, Lee WH, Vies WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159:1815-1826.
60. 3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 2004; 23:3945-3952.
61. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 2002; 183:147-153.
62. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002; 13:293-300.
63. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and I-buthionine-sulfoximine. Cell Death Differ 2004; 11:737-746.
64. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61:5432-5440.
65. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002; 73:61-73.